Use of Indocyanine Green Fluorescence (ICG) as an alternative for sentinel node identification in breast cancer: Experience in a third level center

DOI: 10.17605/OSF.IO/4HA29

Bustamante Silva LA. et al. Use of Indocyanine Green Fluorescence (ICG) as an alternative for sentinel node identification in breast cancer: Experience in a third level center. Am J Med Surg. February 2022; 7(1). 9-13

BACKGROUND: Sentinel lymph node biopsy is based on two main precepts: The anatomical support of the existence of an orderly and predictable pattern of lymphatic drainage towards a regional lymph node and the functioning of a first node as an effective relay site that filters neoplastic cells.

Since that demonstration to achieving the concept of sentinel lymph node biopsy in breast tumors that is currently performed, it has gone through great changes, from the use of colloid gold, patent blue and finally the use of gamma probe (lymphoscintigraphy and radioimaging-guided biopsy), which represents the diagnostic method that, combined with a dye, offers the best performance in our time. Recently, the use of indocyanine green fluorescence as a means of identifying the sentinel node has shown good results and is considered an alternative in centers that do not have the necessary infrastructure to use nuclear medicine.

 

KEY WORDS: Sentinel lymph node, Indocyanine Green Fluorescence.